Jump to content

ABT-418

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Rjwilmsi (talk | contribs) at 13:06, 6 June 2018 (10.1176/ajp.156.12.1931). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

ABT-418
Identifiers
  • 3-Methyl-5-[(2S)-1-methylpyrrolidin-2-yl]-1,2-oxazole
CAS Number
PubChem CID
ChemSpider
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC9H14N2O
Molar mass166.22 g·mol−1
3D model (JSmol)
  • CC1=NOC(=C1)[C@@H]2CCCN2C
  • InChI=1S/C9H14N2O/c1-7-6-9(12-10-7)8-4-3-5-11(8)2/h6,8H,3-5H2,1-2H3/t8-/m0/s1 checkY
  • Key:ILLGYRJAYAAAEW-QMMMGPOBSA-N checkY
 ☒NcheckY (what is this?)  (verify)

ABT-418 is a drug developed by Abbott, that has nootropic, neuroprotective and anxiolytic effects,[1][2][3][4][5] and has been researched for treatment of both Alzheimer's disease[6] and ADHD.[7][8][9] It acts as an agonist at neural nicotinic acetylcholine receptors, subtype-selective binding with high affinity to the α4β2, α7/5-HT3, and α2β2 nicotinic acetylcholine receptors but not the α3β4 subtype[10][11] familiar to nicotine. ABT-418 was reasonably effective for both applications and fairly well tolerated, but produced some side effects, principally nausea, and it is unclear whether ABT-418 itself will proceed to clinical development or if another similar drug will be used instead.[12]

See also

References

  1. ^ Arneric SP, Sullivan JP, Briggs CA, Donnelly-Roberts D, Anderson DJ, Raszkiewicz JL, Hughes ML, Cadman ED, Adams P, Garvey DS (July 1994). "(S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization". J. Pharmacol. Exp. Ther. 270 (1): 310–8. PMID 7518514.
  2. ^ Decker MW, Brioni JD, Sullivan JP, Buckley MJ, Radek RJ, Raszkiewicz JL, Kang CH, Kim DJ, Giardina WJ, Wasicak JT (July 1994). "(S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization". J. Pharmacol. Exp. Ther. 270 (1): 319–28. PMID 7913497.
  3. ^ Brioni JD, O'Neill AB, Kim DJ, Buckley MJ, Decker MW, Arneric SP (October 1994). "Anxiolytic-like effects of the novel cholinergic channel activator ABT-418". J. Pharmacol. Exp. Ther. 271 (1): 353–61. PMID 7965735.
  4. ^ Prendergast MA; Terry AV; Jackson WJ; et al. (April 1997). "Improvement in accuracy of delayed recall in aged and non-aged, mature monkeys after intramuscular or transdermal administration of the CNS nicotinic receptor agonist ABT-418". Psychopharmacology. 130 (3): 276–284. doi:10.1007/s002130050240. PMID 9151363.
  5. ^ Dallanoce, Clelia; Magrone, Pietro; Matera, Carlo; Lo Presti, Leonardo; De Amici, Marco; Riganti, Loredana; Clementi, Francesco; Gotti, Cecilia; De Micheli, Carlo (2010-12-01). "Synthesis of novel chiral Δ2-isoxazoline derivatives related to ABT-418 and estimation of their affinity at neuronal nicotinic acetylcholine receptor subtypes". European Journal of Medicinal Chemistry. 45 (12): 5594–5601. doi:10.1016/j.ejmech.2010.09.009.
  6. ^ Potter A, Corwin J, Lang J, Piasecki M, Lenox R, Newhouse PA (March 1999). "Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease". Psychopharmacology. 142 (4): 334–342. doi:10.1007/s002130050897. PMID 10229057.
  7. ^ Wilens TE, Biederman J, Spencer TJ, Bostic J, Prince J, Monuteaux MC, Soriano J, Fine C, Abrams A, Rater M, Polisner D (December 1999). "A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder". Am J Psychiatry. 156 (12): 1931–7. doi:10.1176/ajp.156.12.1931. PMID 10588407.
  8. ^ Horrigan JP (April 2001). "Present and future pharmacotherapeutic options for adult attention deficit/hyperactivity disorder". Expert Opin Pharmacother. 2 (4): 573–586. doi:10.1517/14656566.2.4.573. PMID 11336608.
  9. ^ Spencer T, Biederman J (2002). "Non-stimulant treatment for Attention-Deficit/Hyperactivity Disorder". J Atten Disord. 6 Suppl 1: S109–19. PMID 12685525.
  10. ^ Papke RL, Thinschmidt JS, Moulton BA, Meyer EM, Poirier A (February 1997). "Activation and inhibition of rat neuronal nicotinic receptors by ABT-418". Br. J. Pharmacol. 120 (3): 429–438. doi:10.1038/sj.bjp.0700930. PMC 1564486. PMID 9031746.
  11. ^ Briggs CA, McKenna DG, Piattoni-Kaplan M (June 1995). "Human alpha 7 nicotinic acetylcholine receptor responses to novel ligands". Neuropharmacology. 34 (6): 583–590. doi:10.1016/0028-3908(95)00028-5. PMID 7566493.
  12. ^ Wilens TE, Decker MW (October 2007). "Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition". Biochem. Pharmacol. 74 (8): 1212–1223. doi:10.1016/j.bcp.2007.07.002. PMC 2974320. PMID 17689498.

Template:Nootropics


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=ABT-418&oldid=844686123"